The Food and Drug Ad ministration (FDA) approved the use of the COX-2 non-steroidal anti-inflammatory agent/analgesic celecoxib, widely known as Celebrex, in children with juvenile or rheumatoid arthritis (JRA) on Dec. 15,2006. While this is not a significant scientific advancement in the treatment of children with JRA, celecoxib is an important additional therapeutic option to treat the symptoms of this disease.

Through a coordinated, collaborative effort, the AAP Section on Rheumatology, in partnership with a number of individuals and organizations,was integral to the FDA's final decision. Nine individuals testified Nov. 29 before the FDA's Arthritis Advisory Committee, which would recommend whether to approve the use of celecoxib in children with JRA to the FDA. The father of a young child with JRA and a young adult with the disease told their stories from the patient perspective. Seven pediatric rheumatologists also testified,including those representing the Academy, the Arthritis Foundation and the...

You do not currently have access to this content.